IMMUNOPROLIFERATIVE DISORDERS
Clinical trials for IMMUNOPROLIFERATIVE DISORDERS explained in plain language.
Never miss a new study
Get alerted when new IMMUNOPROLIFERATIVE DISORDERS trials appear
Sign up with your email to follow new studies for IMMUNOPROLIFERATIVE DISORDERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Scientists test 'Kill Switch' in Cancer-Fighting immune cells
Disease control OngoingThis early-stage study is testing the safety of a new type of personalized cell therapy for adults with B-cell lymphoma that has come back or not responded to other treatments. Doctors take a patient's own immune cells (T cells), modify them in a lab to better target cancer, and …
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Supercharged immune cells target stubborn lymphoma
Disease control OngoingThis study is testing a new cell therapy for people whose Hodgkin's or Non-Hodgkin's lymphoma has come back or hasn't responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better target cancer cells, and then infuse them back into th…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Supercharged immune cells take aim at tough lymphomas in groundbreaking trial
Disease control OngoingThis study is testing a new type of personalized cell therapy for adults whose CD30+ lymphomas have come back or not responded to standard treatments. Doctors take a patient's own immune cells (T cells), genetically modify them to better find and attack cancer cells, and then inf…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Engineered 'Living Drug' with emergency 'Off Switch' tested for tough leukemia cases
Disease control OngoingThis study is testing a new type of treatment for people whose acute lymphoblastic leukemia (ALL) has come back or hasn't responded to other therapies. Doctors take a patient's own immune cells (T cells), genetically modify them to better find and attack leukemia cells, and add a…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC